Insights From the Apremilast After Switching From Fumaric Acid Ester Treatment (APART) Study: An Interim Real-World Safety Analysis

Mrowietz U, Ertner K, Sticherling M, Grosse V, Popp G, Schwichtenberg U, Karl L, Schenck F, Ramaker-Brunke J, Roemmler-Zehrer J, Helget U, Gomez NN (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Journal der Deutschen Dermatologischen Gesellschaft Wiley-Blackwell

Publisher: WILEY

City/Town: HOBOKEN

Pages Range: 21-22

Conference Proceedings Title: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Authors with CRIS profile

Michael Sticherling Professur für Dermatologie

Involved external institutions

licca Klinik für operative Medizin DE Germany (DE) Celgene GmbH DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE)

How to cite

APA:

Mrowietz, U., Ertner, K., Sticherling, M., Grosse, V., Popp, G., Schwichtenberg, U.,... Gomez, N.N. (2020). Insights From the Apremilast After Switching From Fumaric Acid Ester Treatment (APART) Study: An Interim Real-World Safety Analysis. In JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (pp. 21-22). HOBOKEN: WILEY.

MLA:

Mrowietz, Ulrich, et al. "Insights From the Apremilast After Switching From Fumaric Acid Ester Treatment (APART) Study: An Interim Real-World Safety Analysis." Proceedings of the JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT HOBOKEN: WILEY, 2020. 21-22.

BibTeX: Download